MARKSANS — Marksans Pharma Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousMid CapHigh Flyer

Annual income statement for Marksans Pharma, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2020 March 31st	2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IAS	IAS	IAS	IAS	IAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	11,342	13,762	14,908	18,521	21,774
Cost of Revenue
Gross Profit	5,429	7,576	7,428	9,308	10,832
Selling / General / Administrative Expenses
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	9,686	10,727	12,767	15,536	17,891
Operating Profit	1,656	3,035	2,141	2,985	3,883
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	1,572	3,022	2,475	3,377	4,235
Provision for Income Taxes
Net Income After Taxes	1,208	2,385	1,868	2,653	3,149
Minority Interest
Net Income Before Extraordinary Items
Net Income	1,170	2,359	1,846	2,663	3,137
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	1,170	2,359	1,846	2,663	3,137
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	2.97	5.88	4.51	6.42	7.19
Dividends per Share